Single photon emission computed tomography experience with (S)-5-[ 123I]iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers

Synapse

Volumn 63, Issue 4, 2009, Pages 339-358

  Brašić, James Robert ^a   Zhou, Yun ^a   Musachio, John L ^a   Hilton, John ^a   Fan, Hong ^a   Crabb, Andrew ^a   Endres, Christopher J ^a   Reinhardt, Melvin J ^a   Dogan, Ahmet S ^a   Alexander, Mohab ^a   Rousset, Olivier ^a   Maris, Marika A ^a   Galecki, Jeffrey ^a   Nandi, Ayon ^a   Wong, Dean F ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Binding; Density; Distribution; Infusions; Safety; Tomography; Treatment efficacy

Indexed keywords

5 [IODINE 123]IODO 3 (2 AZETIDINYLMETHOXY)PYRIDINE; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; PYRIDINE DERIVATIVE; RADIOLIGAND; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BINDING AFFINITY; BLOOD PRESSURE; BRAIN REGION; COGNITION; CONTROLLED STUDY; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; LIGAND BINDING; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING;

ADULT; AZETIDINES; BRAIN; BRAIN MAPPING; FEMALE; FUNCTIONAL LATERALITY; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PYRIDINES; SMOKING; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YOUNG ADULT;

EID: 63049095919     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20611     Document Type: Article

References (122)

1. American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders,4th ed.Text Revision (DSM-IV-TR™). Washington, DC: APA.
2. Balfour DJK, Fagerström KO. 1996. Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol Ther 72:51-81.
3. 123I]5-IA-85380 in baboon brain and plasma. Nucl Med Biol 33:549-554.
4. 3H]nicotine binding sites in human brain. J Neurochem 50:1243-1247.
5. Bordia T, Parameswaran N, Fan H, Langston JW, McIntosh JM, Quik M. 2006. Partial recovery of striatal nicotinic receptors in 1-methy-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-lesioned monkeys with chronic oral nicotine. J Pharmacol Exp Ther 319:285-292.
6. 18F-fluoro-A-85380 in healthy volunteers. J Nucl Med 44:596-601.
7. Brašić JR. 2003. Treatment of movement disorders in autism spectrum disorders. In: Hollander E, editor. Autism spectrum disorders, Vol. 24 of the Medical Psychiatry Series. ISBN 0-8247-0715-X. p. 273-346. New York: Marcel Dekker.
8. Brašić JR, Musachio JL, Zhou Y, Cascella N, Nestadt G, Osman M, Gay O, Hilton J, Kuwabara H, Crabbe A, Rousset O, Fan H, Al-Humadi MA, Al-Humadi BA, Arkles JS, Thompson T, Kalaff A, Smith J, Reinhardt MJ, Dogan AS, Ford B, Wong DF. 2001. Neuropsychiatric assessment of [123I]iodo-3-(2 azetidinylmethoxy)pyridine. Mov Disord 16(Suppl 1):S54 [abstract].
9. Brašić JR, Bronson B, Chun TT. 2008. Tardive dyskinesia. eMedicine. Available at http://www.emedicine.com/neuro/topic362.htm.
10. Brašić JR, Wong D, Eroglu A. 2007. PET scanning in autism spectrum disorders. Emedicine. Available at http://www.emedicine.-com/neuro/ topic440.htm
11. 3H]nicotine binding in human postmortem brain. J Pharmacol Exp Ther 282;7-13.
12. Breese CR, Lee MJ, Adams CE, Sullivan B, Logel J, Gillen KM, Marks MJ, Collins AC, Leonard S. 2000. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 23:351-364.
13. Bridevaux P-O, Cornuz J, Gaspoz J-M, Burnand B, Ackermann-Liebrich U, Schindler C, Leuenberger P, Rochat T, Gerbase MW; SAPALDIA Team. 2007. Secondhand smoke and health-related quality of life in never smokers: results from the SAPALDIA Cohort Study 2. Arch Intern Med 167:2516-2523.
14. 2 nicotinic acetylcholine receptors. Arch Gen Psychiatry 63:907-915.
15. Bruintjes G, Krantz MJ. 2007. Acute vs chronic secondhand smoke exposure. Arch Intern Med 167:731. [letter]
16. 18F]norchloro-fluoro- homoepibatidine. Synapse 62:205-218.
17. Buccafusco JJ, Terry AV Jr, Decker MW, Gopalakrishnan M. 2007. Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys. Biochem Pharmacol 74:1202-1211.
18. Buisson B, Bertrand D. 2001. Chronic exposure to nicotine upregulates the human α4β2 nicotinic acetylcholine receptor function. J Neurosci 21:1819-1829.
19. 123I]iodo-A-85380 using single photon emission computed tomography. Life Sci 63:PL355-PL360.
20. 2 nicotinic acetylcholine receptors. Neuro-Report 10:2715-2721.
21. Chefer SI, Pavlova OA, Zhang Y, Vaupel DB, Kimes AS, Horti AG, Stein E, Mukhin AG. 2008. NIDA522131, a new radioligand for imaging extrathalamic nicotinic acetylcholine receptors: In vitro and in vivo evaluation. J Neurochem 104:306-315.
22. 123I-5IA-85380 SPECT study. J Neurol Neurosurg Psychiatry 79:485-487.
23. Conover WJ. 1980. Practical Nonparametric Statistics, 2nd ed. New York: Wiley. p. 122-129, 216-223.
24. 123I-5-IA-85380 SPECT imaging of nicotinic acetylcholine receptor availability in nonsmokers: effects of sex and menstrual cycle. J Nucl Med 48;1633-1640.
25. Court JA, Lloyd S, Thomas N, Piggott MA, Marshall EF, Morris CM, Lamb H, Perry RH, Johnson M, Perry EK. 1998. Dopamine and nicotinic receptor binding and levels of dopamine and homovanillic acid in human brain related to tobacco use. Neuroscience 87:63-78.
26. De Luca V, Voineskos S, Wong G, Kennedy JL. 2006. Genetic interaction between α4 and β2 subunits of high affinity nicotinic receptor: analysis in schizophrenia. Exp Brain Res 174:292-296.
27. Denckla MB. 1985. Revised neurological examination for subtle signs. 1985. Psychopharmacol Bull 21(4):773-800.
28. 18F]F-A-85380 on nicotinic acetylcholine receptors in the porcine brain in vitro. Synapse 59:201-210.
29. 18F]fluoro-3-(2(S)- azetidinylmethoxy) pyridine as a PET tracer for nicotinic acetylcholine receptors. Nucl Med Biol 27:381-389.
30. Dollé F, Dolci L, Valette H, Hinnen F, Vaufrey F, Guenther I, Fuseau C, Coulon C, Bottlaender M, Crouzel C. 1999. Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2- azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors. J Med Chem 42:2251-2259.
31. Durany N, Zöchling R, Boissl KW, Paulus W, Ransmayr G, Tatschner T, Danielczyk W, Jellinger K, Deckert J, Riederer P. 2000. Human post-mortem striatal 7alpha;4β2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome. Neurosci Lett 287:109-112.
32. Dursun SM, Reveley MA. 1996. The efficacy of a dose-escalated application of transdermal nicotine plus sulpiride in Tourette's syndrome. Eur Psychiatry 11:204-206.
33. Dursun SM, Reveley MA. 1997. Differential effects of transdermal nicotine on microstructured analyses of tics in Tourette's syndrome: an open study. Psychol Med 27:483-487.
34. 18F-nifene: a measure of acetylcholine competition. Synapse 61:29-36.
35. Eisner MD, Wang Y, Haight TJ, Balmes J, Hammond SK, Tager IB. 2007. Secondhand smoke exposure, pulmonary function, and cardiovascular mortality. Ann Epidemiol 17:364-373.
36. Elazar Z, Paz M. 1999. Potentiation of haloperidol catalepsy by microinjections of nicotine into the striatum or pons in rats. Life Sci 64:1117-1125.
37. 123I]5-I-A-85380 SPECT. J Nucl Med 41:1552-1560.
38. 123I]5-I-A-85380 in healthy human subjects. Eur J Nucl Med Mol Imaging 29:183-190.
39. Fujita M, Ichise M, Zoghbi SS, Liow J-S, Ghose S, Vines DC, Sangare J, Lu J-Q, Cropley VL, Iida H, Kim KM, Cohen RM, Bara-Jimenez W, Ravina B, Innis RB. 2006. Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease. Ann Neurol 59:174-177.
40. 18F-fluoro-A-85380 and PET. J Nucl Med 46:240-247.
41. Gotti C, Fornasari D, Clementi F. 1997. Human neuronal nicotinic receptors. Prog Neurobiol 53:199-237.
42. Gozzi A, Schwarz A, Reese T, Bertani S, Crestan V, Bifone A. 2006. Region-specific effects of nicotine on brain activity: A pharmacological MRI study in the drug-naïve rat. Neuropsychopharmacology 31:1690-1703.
43. Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF. 2000. Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol 27:627-630.
44. 18F]fluoro-A-85380, a novel radioligand for in vivo imaging of central nicotinic acetylcholine receptors. Life Sci 67:463-469.
45. Huang LZ, Winzer-Serhan UH. 2006. Chronic neonatal nicotine upregulates heteromeric nicotinic acetylcholine receptor binding without change in subunit mRNA expression. Brain Res 1113:94-109.
46. Hui X, Gao J, Xie X, Suto N, Ogiku T, Wang M-W. 2005. A robust homogeneous binding assay for α4α2 nicotinic acetylcholine receptor. Acta Pharmacol Sin 26:1175-1180.
47. Ishizu K, Mamede M, Ueda M, Mukai T, Iida Y, Saji H, Saga T. 2004. Nicotinic acetylcholine receptors before and after cigarette withdrawal in smokers: quantitative 5IA-SPECT study. Neuro-Image 22(Suppl 2):T114 [abstract].
48. Jacob P III, Wilson M, Benowitz NL. 1981. Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids. J Chromatogr 222:61-70.
49. Kassiou M, Bottlaender M, Loc'h C, Dolle F, Musachio JL, Coulon C, Ottaviani M, Dannals RF, Maziere B. 2002. Pharmacological evaluation of a Br-76 analog of epibatidine: A potent ligand for studying brain nicotinic acetylcholine receptors. Synapse 45:95-104.
50. Kassiou M, Eberl S, Meikle SR, Birrell A, Constable C, Fulham MJ, Wong DF, Musachio JL. 2001. In vivo imaging of nicotinic receptor upregulation following chronic (-)-nicotine treatment in baboon using SPECT. Nuc Med Biol 28:165-175.
51. Kawakami N, Takatsuka N, Inaba S, Shimizu H. 1999. Developmental of a screening questionnaire for tobacco/nicotine dependence according to ICD-10, DSM-III-R, and DSM-IV. Addict Behav 24:155-166.
52. 18F]F-A85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans. FASEB J 17:1331-1333. Published online May 20, 2003, doi:10.1096/fj. 02-0492fje.
53. Koren AO, Horti AG, Mukhin AG, Gündisch D, Kimes AS, Dannals RF, London ED. 1998. 2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy) pyridines: Synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling. J Med Chem 41:3690-3698.
54. Lammertsma AA, Hume SP. 1996. Simplified reference tissue model for PET receptor studies. Neuroimage 4:153-158.
55. Léna C, Changeux J-P. 1998. Allosteric nicotinic receptors, human pathologies. J Physiol Paris 92:63-74.
56. Leonard S, Bertrand D. 2001. Neuronal nicotinic receptors: From structure to function. Nicotine Tob Res 3:203-223.
57. Leonard S, Breese CR, Lee MJ, Logel J, Adams CE, Freedman R. 1999. Abnormal regulation of high affinity nicotine receptors in schizophrenia. Schizophr Res 36(1-3 special issue):74 [abstract].
58. Leonard S, Gault J, Adams C, Breese CR, Rollins Y, Adler LE, Olincy A, Freedman R. 1998. Nicotinic receptors, smoking and schizophrenia. Restor Neurol Neurosci 12:195-201.
59. 123I-5IA SPECT. J Nucl Med 45:1458-1470.
60. Mamede M, Ishizu K, Ueda M, Mukai T, Iida Y, Kawashima H, Fukuyama H, Togashi K, Saji H. 2007. Temporal change in human nicotinic acetylcholine receptor after smoking cessation: 5IA SPECT study. J Nucl Med 48:1829-1835.
61. McCallum SE, Parameswaran N, Bordia T, Fan H, McIntosh JM, Quik M. 2006. Differential regulation of mesolimbic α3*/α6β2* and α4β2* nicotinic acetylcholine receptor sites and function after long-term oral nicotine to monkeys. J Pharmacol Exp Ther 318:381-388.
62. Mihailescu S, Drucker-Colín R. 2000. Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Med Res 31:131-144.
63. 18F]F-A-85380 PET. Nucl Med Biol 32:585-591.
64. 2-nicotinic acetylcholine receptor availability in the aging human brain. Ann NY Acad Sci 1097:168-170.
65. Mogg AJ, Jones FA, Pullar IA, Sharples CGV, Wonnacott S. 2004. Functional responses and subunit composition of presynaptic nicotinic receptor subtypes explored using the novel agonist 5-iodo-A-85380. Neuropharmacology 47:848-859.
66. Moroni M, Zwart R, Sher E, Cassels BK, Bermudez I. 2006. α4β2 nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine. Mol Pharmacol 70:755-768.
67. Mukhin AG, Gündisch D, Horti AG, Koren AO, Tamagnan G, Kimes AS, Chambers J, Vaupel DB, King SL, Picciotto MR, Innis RB, London ED. 2000. 5-Iodo-A-85380, an α4β2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol Pharmacol 57: 642-649.
68. Musachio JL, Scheffel U, Finley PA, Zhan Y, Mochizuki T, Wagner HN Jr, Dannals RF. 1998. 5-[I-125/123]Iodo-3(2(S)-azetidinylmethoxy) pyridine, a radioiodinated analog of A-85380 for in vivo studies of central nicotinic acetylcholine receptors. Life Sci 62: PL351-PL357.
69. Musachio JL, Villemagne VL, Scheffel UA, Dannals RF, Dogan AS, Yokoi F, Wong DF. 1999. Synthesis of an I-123 analog of A-85380 and preliminary SPECT imaging of nicotinic receptors in baboon. Nucl Med Biol 26:201-207.
70. Musachio JL, Brašić JR, Scheffel UA, Rauseo PA, Fan H, Osman M, Kellar KJ, Xiao Y, Hilton J, Zhou Y, Wong DF. 2001. Radiosynthesis, in vitro/in vivo pharmacologic characterization, and initial human SPECT imaging studies with [I-123] 5-Iodo-A-85380: A high affinity nicotinic acetylcholine receptor (nAChR) radioprobe. Presented at American Chemical Society Meeting, Abstracts of papers - ACS, Vol. 221(Part 2). Washington, DC: American Chemical Society. p183-NUCL [abstract].
71. National Institute of Mental Health, Alcohol, Drug Abuse, and Mental Health Administration, Public Health Service, Department of Health, Education and Welfare. 1988. Abnormal Involuntary Movement Scale (AIMS). Psychopharmacol Bull 24(4):781-783.
72. Newhouse PA, Kelton M. 2000. Nicotinic systems in central nervous systems disease: Degenerative disorders and beyond. Pharm Acta Helv 74:91-101.
73. Nguyen HN, Rasmussen BA, Perry DC. 2003. Subtype-selective upregulation by chronic nicotine of high-affinity nicotinic receptors in rat brain demonstrated by receptor autoradiography. J Pharmacol Exp Ther 307:1090-1097.
74. Nicolotti O, Pellegrini-Calace M, Carrieri A, Altomare C, Centeno NB, Sanz F, Carotti A. 2001. Neuronal nicotinic receptor agonists: a multi-approach development of the pharmacophore. J Comput Aided Mol Des 15:859-872.
75. 123I-5IA-85380 single-photon-emission computed tomography. J Neurol Neurosurg Psychiatry 78:356-362.
76. 18F]fluoro-A-85380 in human PET imaging studies. Nucl Med Biol 32:869-874.
77. 123I-5IA SPECT. Mov Disord 21(Suppl 15): S568. [abstract]
78. 123I-5IA SPECT. J Neurol Sci 256:52-60.
79. Overall JE, Gorham DR. 1962. The Brief Psychiatric Rating Scale. Psychol Rep 10:799-812.
80. Paterson D, Nordberg A. 2000. Neuronal nicotinic receptors in the human brain. Prog Neurobiol 61:75-111.
81. Perry DC, Dávila-Garc?́a MI, Stockmeier CA Kellar KJ. 1999. Increased nicotinic receptors in brains from smokers: Membrane binding and autoradiography studies. J Pharmacol Exp Ther 289;1545-1552.
82. Picard F, Bruel D, Servent D, Saba W, Fruchart-Gaillard C, Schöllhorn-Peyronneau M-A, Roumenov D, Brodtkorb E, Zuberi S, Gambardella A, Steinborn B, Hufnagel A, Valette H, Bottlaender M. 2006. Alteration of the in vivo nicotinic receptor density in ADN-FLE patients: A PET study. Brain 129:2047-2060.
83. Pocivavsek A, Icenogle L, Levin ED. 2006. Ventral hippocampal α7 and α4β2 nicotinic receptor blockade and clozapine effects on memory in female rats. Psychopharmacology (Berl) 188:597-604.
84. Rosenthal R. 1991. Meta-analytic procedures for social research, revised. Newbury Park, California: Sage. p 19.
85. 2 nicotinic acetylcholine receptor. CNS Drug Rev 12:100-112.
86. Saji H, Ogawa M, Ueda M, Iida Y, Magata Y, Tominaga A, Kawashima H, Kitamura Y, Nakagawa M, Kiyono Y, Mukai T. 2002. Evaluation of radioiodinated 5-iodo-3-(2(S)-azetidinylmethoxy)pyridine as a ligand for SPECT investigations of brain nicotinic acetylcholine receptors. Ann Nucl Med 16:189-200.
87. Sanberg PR, Silver AA, Shytle RD, Philipp MK, Cahill DW, Fogelson HM, McConville BJ. 1997. Nicotine for the treatment of Tourette's syndrome. Pharmacol Ther 74:21-25.
88. Schapira M, Abagyan R, Totrov M. 2002. Structural model of nicotinic acetylcholine receptor isotypes bound to acetylcholine and nicotine. BMC Struct Biol 2:1. Available at http://www.biomedcentral. com/1472-6807/2/1.
89. 18F]Fluoro-A-85380: An in vivo tracer for the nicotinic acetylcholine receptor. Nucl Med Biol 27:51-56.
90. 18F]F-A-85380). Appl Radiat Isot 65:1244-1248.
91. Shytle RD, Silver AA, Sanberg PR. 2000. Comorbid bipolar disorder in Tourette's syndrome responds to the nicotinic receptor antagonist mecamylamine (Inversine). Biol Psychiatry 48:1028-1031.
92. Silver AA, Shytle RD, Philipp MK, Sanberg PR. 1996. Case study: Long-term potentiation of neuroleptics with transdermal nicotine in Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 35:1631-1636.
93. Smith JW, Mogg A, Tafi E, Peacey E, Pullar IA, Szekeres P, Tricklebank M. 2007. Ligands selective for α4β2 but not α3β4 or α7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat. Psychopharmacology (Berl) 190:157-170.
94. 18F]fluoro-A-85380 and its metabolites in human blood during PET investigation: A methodological study. Nucl Med Biol 34:331-342.
95. SPSS Inc. 2007. SPSS Base 16.0 User's Guide. Chicago: SPSS. p 528-529, 531-532.
96. 123I-5-IA-85380 SPECT measurement of nicotinic acetylcholine receptors in human brain by the constant infusion paradigm: Feasibility and reproducibility. J Nucl Med 46:1466-1472.
97. 2*nicotinic acetylcholine receptors than nonsmokers. J Neurosci 26:8707-8714.
98. Stranges S, Bonner MR, Fucci F, Cummings KM, Freudenheim JL, Dorn JM, Muti P, Giovino GA, Hyland A, Trevisan M. 2007. Acute vs chronic secondhand smoke exposure. In reply. Arch Intern Med 167:731-732. [letter]
99. Trauth JA, Seidler FJ, McCook EC, Slotkin TA. 1999. Adolescent nicotine exposure causes persistent upregulation of nicotinic cholinergic receptors in rat brain regions. Brain Res 851:9-19.
100. Tüzün E. 2006. Neuronal acetylcholine receptor alpha 9-subunit: A possible central nervous system autoantigen. Med Hypotheses 67:561-565.
101. 123I]Iodo-A-85380: Assessment of pharmacological safety, radiation dosimetry and SPECT imaging of brain nicotinic receptors in healthy human subjects. Ann Nucl Med 18:337-344.
102. 18F]fluoro-A-85380. J Nucl Med 40:1374-1380.
103. 125I]5-I-A-85380, a nicotinic acetylcholine receptor radioligand. Neuroreport 13:2311-2317.
104. Vaupel DB, Tella SR, Huso DL, Wagner VO, III, Mukhin AG, Chefer SI, Horti AG, London ED, Koren AO, Kimes AS. 2005. Pharmacological and toxicological evaluation of 2-flouro-3-(2(S)-azetidinylmethoxy) pyridine (2-F-A-85380), a ligand for imaging cerebral nicotinic acetylcholine receptors with positron emission tomography. J Pharmacol Exp Ther 312:355-365.
105. Villemagne VL, Musachio JL, Scheffel U. 1998. Nicotine and related compounds as PET and SPECT ligands. In: Arneric SP, Brioni JD, editors. Neuronal nicotinic receptors: Pharmacology and therapeutic opportunities. New York: Wiley-Liss. p 235-250.
106. Voineskos S, De Luca V, Mensah A, Vincent JB, Potapova N, Kennedy JL. 2007. Association of alpha4beta2 nicotinic receptor and heavy smoking in schizophrenia. J Psychiatry Neurosci 32:412-416.
107. Wong DF, Brašić JR. 2001. In vivo imaging of neurotransmitter systems in neuropsychiatry. Clin Neurosci Res 1:35-45.
108. 123I5-iodo-A-85380. J Nucl Med 42(Suppl 5):142P [abstract].
109. Wong DF Jr, Maini A, Alexander M, Zhou Y, Brasic J, Scheffel U, Fan H, Hilton J, Dannals R, Musachio J. 2002a. Imaging nicotinic receptors in the development of allosteric potentiating ligands for cognitive enhancement in Alzheimers dementia. J Nucl Med 43(Suppl 5):109P-110P [abstract].
110. Wong DF, Maini A, Rousset OG, Brašić JR. 2003. Positron emission tomography-A tool for identifying the effects of alcohol dependence on the brain. Alcohol Res Health 27:161-173. Available at http://pubs.niaaa.nih. gov/publications/arh27-2/161-173.pdf.
111. Wong DF, Potter WZ, Brašić JR. 2002b. Proof of concept: Functional models for drug development in humans. In: Davis KL, Charney D, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology: The fifth generation of progress. Baltimore: The American College of Neuropsychopharmacology and Lippincott Williams & Wilkins. p 457-473.
112. Wonnacott S. 1990. The paradox of nicotinic acetylcholine receptor upregulation by nicotine. Trends Pharmacol Sci 11:216-219.
113. Wüllner U, Gündisch D, Herzog H, Minnerop M, Joe A, Warnecke M, Jessen F, Schütz C, Reinhardt M, Eschner W, Klockgether T, Schmaljohann J. 2008. Smoking upregulates α4β2* nicotinic acetylcholine receptors in the human brain. Neurosci Lett 430:34-37.
114. Yokoi F, Musachio J, Hilton J, Kassiou M, Ravert HT, Mathews WB, Dannals RF, Stephane M, Wong DF. 1999. Kinetic modeling of nicotinic acetylcholine receptor ligand, [C11]A-84543 in a baboon PET study. J Nucl Med 40 (Suppl 5):263P [abstract].
115. Yoshida H, Inoue M, Oyanagi C, Katsumi Y, Mukai T, Ishizu K, Hashikawa K, Fukuyama H. 2002. Nicotinic acetylcholine receptors in Alzheimer's disease: 5IA-SPECT study. Neuroimage 16(3) (Part 2 of two parts):S103 [abstract].
116. Zamani MR, Allen YS. 2001. Nicotine and its interaction with β-amyloid protein: A short review. Biol Psychiatry 49:221-232.
117. Zaniewska M, McCreary AC, Przegaliński E, Filip M. 2006. Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats. Eur J Pharmacol 540:96-106.
118. 2C receptor ligands on the discriminative stimulus effects of nicotine in rats.Eur J Pharmacol 571:156-165.
119. 123I]iodo-5-I- A-85380 dynamic SPECT studies in normals: Kinetic analysis and parametric imaging. In Nuclear Science Symposium Conference Record, 2001 IEEE 3:1335-1340.
120. Zoghbi SS, Tamagnan G, Fujita M, Baldwin RM, Amici L, Seibyl JP, Innis RB. 1999. Metabolism of 5-I-123-Iodo-3-(2(3)-azetidinylmethoxy) pyridine, a nicotinic acetylcholine receptor imaging agent, in non-human primates. J Labelled Comp Radiopharm 42(Suppl 1):S666-S668.
121. 123I]iodo-3-(2-azetidinylmethoxy)pyridine (5-IA-85380), a nicotinic acetylcholine receptor imaging agent, in nonhuman primates. Nucl Med Biol 28:91-96.
122. Zwart R, Broad LM, Xi Q, Lee M, Moroni M, Bermudez I, Sher E. 2006. 5-I A-85380 and TC-2559 differentially activate heterologously expressed α4β2 nicotinic receptors. Eur J Pharmacol 539:10-17.